News | Treatment Planning | October 31, 2018

Mirada Medical Showcases DLCExpert AI-Based Radiotherapy Contouring Software at ASTRO 2018

Artificial intelligence software brings quality and consistency to the task of contouring critical structures for radiation treatment planning

Mirada Medical Showcases DLCExpert AI-Based Radiotherapy Contouring Software at ASTRO 2018

October 31, 2018 — Medical imaging software company Mirada Medical showcased its DLCExpert at the recent American Society for Radiation Oncology (ASTRO) 2018 annual meeting, oct. 21-24 in San Antonio, Texas. The product, which has received U.S. Food and Drug Administration (FDA) 510(k) clearance, is the world’s first artificial intelligence (AI)-powered autocontouring solution. The software is already in use in multiple academic medical centers worldwide.

DLCExpert automatically generates contours that users often find indistinguishable from those drawn by clinical experts, according to Mirada Medical. The software has been shown to bring quality and consistency to the task of contouring critical structures for radiation treatment planning.

DLCExpert received CE Marking for the European market earlier this year. Medical institutions across Europe are currently commissioning the product to exploit the significant benefits that AI brings to their contouring workflow.

Andre Dekker, professor of clinical data science, Department of Radiation Oncology at the Maastro Clinic in Maastricht, The Netherlands, stated, “The contours generated by DLCExpert are the closest to clinically acceptable contours we’ve seen from any autocontouring system we have evaluated. For some organs, our clinicians found it very hard to distinguish between their own contours and those that were automatically generated”.

U.S. regulatory clearance for DLCExpert was granted as part of the FDA 510(k) for Workflow Box 2.0, Mirada’s Zero-Click automation platform. DLCExpert is available as an option, along with five additional Zero-Click workflows, including multi-modal autocontouring, routing of data and support for the integration of custom applications.

See an example of this technology in the VIDEO: Artificial Intelligence Automatic Contouring and Segmentation For Radiotherapy.

For more information: www.mirada-medical.com

Related Content

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
December 21, 2020 — According to recent studies, an increase in the...
Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy after breast-conserving surgery had higher rates of local recurrence but similar 10-year survival rates when compared to patients who received postoperative radiation therapy, according to updated 10-year data from the PRIME II study, presented at the 2020 San Antonio Breast Cancer Symposium

Getty Images

News | Radiation Therapy | December 15, 2020
December 15, 2020 — Older patients with hormone receptor-positive breast cancer who did not receive radiation therapy
A new study finds that significant symptoms in young and Black patients are more likely to be under-recognized

Getty Images

News | Radiation Therapy | December 10, 2020
December 10, 2020 — Physicians did not recognize side effects from...